# STRIDES PHARMA CANADA INC. BALANCE SHEET AS AT MARCH 31, 2021

	BALANCE SHEET AS A			
			Amount in CAD	Amount in CAD
			31-Mar-21	31-Mar-20
Α	ASSETS			
I	Non-current assets			
	(a) Property, plant and equipment		3,993	1,130
	(b) Intangibles assets under development		298,866	177,330
	(c) Financial assets			
	(i) Investments	1	3,803,196	3,803,196
	Total non-current assets		4,106,055	3,981,656
ı	Current assets			
	(a) Inventories		678,021	-
	(a) Financial assets			
	(i) Trade receivables	2	494,361	3,222
	(ii) Cash and cash equivalents	3	231,562	44,844
	(b) Other current assets	4	793,986	1,855,441
	Total current assets		2,197,930	1,903,507
	TOTAL ASSETS		6,303,985	5,885,163
В	EQUITY AND LIABILITIES			
ı	Equity			
	(a) Equity share capital	5	1,000	1,000
	(b) Other equity	6	5,111,141	5,172,303
	Total Equity		5,112,141	5,173,303
П	Liabilities			
1	Current liabilities			
	(a) Financial liabilities			
	(i) Trade payables	7	454,780	711,860
	(ii) Other financial liabilities	8	597,340	-
	(b) Provisions	9	139,724	
	Total current liabilities	J	1,191,844	711,860
	TOTAL EQUITY AND LIABILITIES		6,303,985	5,885,163

## STRIDES PHARMA CANADA INC. STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2021

## Amount in CAD Amount in CAD

	Particulars	Note No.	31-Mar-21	31-Mar-20
1	Revenue from operations	10	624,458	136,500
2	Other Income	11	186,145	4,132
3	Total Revenue (1+2)	•	810,603	140,632
4	Expenses			
	(a) Cost of goods sold		299,401	-
	(b ) Employee benefits expense	12	527,468	211,593
	(c) Finance costs	13	4,181	1,627
	(d ) Depreciation and amortisation expense		1,130	77
	(e) Other expenses	14	539,585	297,081
	Total expenses		1,371,765	510,378
5	Profit / (Loss) before exceptional items and taxes (3-4)		(561,162)	(369,746)
6	Exceptional Item	•	-	73,289
7	Profit / (Loss) before taxes (5+6)	•	(561,162)	(443,035)
8	Tax Expense: (1) Current tax		_	_
	(2) Deferred tax			- -
	Total tax expenses	•	-	
9	Profit / (Loss) for the year after tax		(561,162)	(443,035)

## STRIDES PHARMA CANADA INC. STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2021

## (A) Equity share capital

Particulars	Amount in CAD
Balance as at March 31, 2020	1,000
Changes in equity share capital during the year	
Balance as at March 31, 2021	1,000

(B) Other equity Amount in CAD

<b></b>			
	Share application	Reserves and surplus	
  Particulars		Surpius	Total
r ai ucuiai s	money		iotai
	pending	Retained earnings	
	allotment		
Balance as at March 31, 2020	6,112,265	(939,962)	5,172,303
Application money received during the year	500,000		500,000
Profit/loss for the year	-	(561,162)	(561,162)
Balance as at March 31, 2021	6,612,265	(1,501,124)	5,111,141

#### STRIDES PHARMA CANADA INC.

#### Notes forming part of financial statement

#### Note

No.

1	Non current investments	Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Pharmapar Inc	3,803,196	3,803,196
Total	3,803,196	3,803,196

#### 2 Trade receivables Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Unsecured		
Considered good	494,361	3,222
Total	494,361	3,222

## 3 Cash and cash equivalents Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Cash in hand		
Balances with banks:		
In current accounts	231,562	44,844
Total	231,562	44,844

#### 4 Other current assets Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Unsecured, considered good		
Loans and advances to Group entities	767,574	1,828,346
Balances with government authorities:	21,479	27,095
Prepaid Expenses	4,934	-
Total	793,986	1,855,441

#### 5 Share capital Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Issued, subscribed and fully paid-up		
Equity share capital	1,000	1,000
Total	1,000	1,000

#### 6 Reserves and surplus Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Share Application money Pending Allotment	6,612,265	6,112,265
	6,612,265	6,112,265
Surplus in statement of profit and loss		
Opening balance	(939,962)	(496,926)
Add: Profit / (Loss) for the year	(561,162)	(443,035)
Closing balance	(1,501,124)	(939,962)
Total	5,111,141	5,172,303

## 7 Trade payables Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Trade payable	454,780	711,860
Total	454,780	711,860

#### Other Current financial Liabilities Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Payable to group entities	576,396	-
Other payables:		
- Statutory remittances	20,943	
Total	597,340	-

#### 9 Provisions Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Provision for expenses	139,724	-
Total	139,724	-

#### STRIDES PHARMA CANADA INC.

## Notes forming part of financial statement

Note

No.

10	Revenue	from	operations
----	---------	------	------------

Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Sale of Product	624,458	136,500
Total	624,458	136,500

## 11 Other Income

Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Other Income	41,982	
Exchange fluctuation gain	32,092	-
Sundry balance written back	6,982	-
Interest Income	105,088	
Total	186,145	-

## 12 Employee Benefit Expenses

Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Salaries and wages	527,468	211,593
Total	527,468	211,593

#### 13 Finance cost

**Amount in CAD** 

Particulars	31-Mar-21	31-Mar-20
Finance Cost	4,181	1,627
Total	4,181	1,627

## 14 Other expenses

Amount in CAD

Particulars	31-Mar-21	31-Mar-20
Freight and forwarding	8,422	-
Coversion & processing charges	117,333	-
Consumables	58,928	-
Sundry Balance of Written back	-	407
Director sitting fees	20,000	20,000
Commission	559	-
General Expenses	23,436	-
Rates & Taxes	132,945	112,417
Repairs & Maintenance	314	
Insurance	1,977	4,056
Conveyance & Travelling	7,277	21,275
Advertising & selling expenses	79,082	-
Membership fees and subcription	17,759	-
Net loss on foreign currency transactions	-	40,516
Professional fees	70,330	98,411
Miscellaneous Expense	1,223	-
Total	539,585	297,081